ImmunoPET of tissue factor expression in triple-negative breast cancer with a radiolabeled antibody Fab fragment

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 42, Issue 8, 2015, Pages 1295-1303

  Shi, Sixiang ^a   Hong, Hao ^b   Orbay, Hakan ^b   Graves, Stephen A ^c   Yang, Yunan ^b   Ohman, Jakob D ^b   Liu, Bai ^d   Nickles, Robert J ^c   Wong, Hing C ^d   Cai, Weibo ^a,b,c,e  

^a University of Wisconsin Madison   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d Altor BioScience   (United States)

^e UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Antibody fragment; Fab; Positron emission tomography (PET); Tissue factor (TF); Triple negative breast cancer (TNBC)

Indexed keywords

1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID MONOCLONAL ANTIBODY ALT 836 IMMUNOGLOBULIN F(AB) FRAGMENT CU 64; CD31 ANTIGEN; THROMBOPLASTIN; TRACER; UNCLASSIFIED DRUG; 64CU-NOTA-ALT-836-FAB; COPPER; IMMUNOGLOBULIN F(AB) FRAGMENT; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONJUGATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG TUMOR LEVEL; FEMALE; FLOW CYTOMETRY; HISTOLOGY; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; UPREGULATION; ANIMAL; CHEMISTRY; DIAGNOSTIC IMAGING; EXPERIMENTAL MAMMARY NEOPLASM; GENETICS; IMMUNOLOGY; METABOLISM; SYNTHESIS; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; COPPER RADIOISOTOPES; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THROMBOPLASTIN; TISSUE DISTRIBUTION; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84932192383     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-015-3038-1     Document Type: Article

References (36)

1. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–48.
2. van Scheltinga AG T, Berghuis P, Nienhuis HH, Timmer-Bosscha H, Pot L, Gaykema SB, et al. Visualising dual downregulation of insulin-like growth factor receptor-1 and vascular endothelial growth factor-A by heat shock protein 90 inhibition effect in triple negative breast cancer. Eur J Cancer. 2014;50:2508–16.
3. Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol. 2010;7:683–92.
4. Callander NS, Varki N, Rao LV. Immunohistochemical identification of tissue factor in solid tumors. Cancer. 1992;70:1194–201.
5. Vrana JA, Stang MT, Grande JP, Getz MJ. Expression of tissue factor in tumor stroma correlates with progression to invasive human breast cancer: paracrine regulation by carcinoma cell-derived members of the transforming growth factor beta family. Cancer Res. 1996;56:5063–70.
6. Jiang X, Bailly MA, Panetti TS, Cappello M, Konigsberg WH, Bromberg ME. Formation of tissue factor-factor VIIa-factor Xa complex promotes cellular signaling and migration of human breast cancer cells. J Thromb Haemost. 2004;2:93–101.
7. Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med. 1996;2:209–15.
8. Ruf W, Yokota N, Schaffner F. Tissue factor in cancer progression and angiogenesis. Thromb Res. 2010;125 Suppl 2:S36–8.
9. Ryden L, Grabau D, Schaffner F, Jonsson PE, Ruf W, Belting M. Evidence for tissue factor phosphorylation and its correlation with protease-activated receptor expression and the prognosis of primary breast cancer. Int J Cancer. 2010;126:2330–40.
10. Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost. 2007;5:520–7.
11. Ueno T, Toi M, Koike M, Nakamura S, Tominaga T. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer. 2000;83:164–70.
12. Hong H, Zhang Y, Nayak TR, Engle JW, Wong HC, Liu B, et al. Immuno-PET of tissue factor in pancreatic cancer. J Nucl Med. 2012;53:1748–54.
13. Jiao JA, Kelly AB, Marzec UM, Nieves E, Acevedo J, Burkhardt M, et al. Inhibition of acute vascular thrombosis in chimpanzees by an anti-human tissue factor antibody targeting the factor X binding site. Thromb Haemost. 2010;103:224–33.
14. Wu AM, Olafsen T. Antibodies for molecular imaging of cancer. Cancer J. 2008;14:191–7.
15. Andrew SM, Pimm MV, Perkins AC, Baldwin RW. Comparative imaging and biodistribution studies with an anti-CEA monoclonal antibody and its F(ab)2 and Fab fragments in mice with colon carcinoma xenografts. Eur J Nucl Med. 1986;12:168–75.
16. Hoeben BA, Kaanders JH, Franssen GM, Troost EG, Rijken PF, Oosterwijk E, et al. PET of hypoxia with 89Zr-labeled cG250-F(ab’)2 in head and neck tumors. J Nucl Med. 2010;51:1076–83.
17. Griffiths GL, Goldenberg DM, Roesch F, Hansen HJ. Radiolabeling of an anti-carcinoembryonic antigen antibody Fab’ fragment (CEA-Scan) with the positron-emitting radionuclide Tc-94m. Clin Cancer Res. 1999;5:3001s–3003s.
18. Yoshida C, Tsuji AB, Sudo H, Sugyo A, Sogawa C, Inubushi M, et al. Development of positron emission tomography probe of 64Cu-labeled anti-C-kit 12A8 Fab to measure protooncogene C-kit expression. Nucl Med Biol. 2011;38:331–7.
19. Zhang Y, Hong H, Orbay H, Valdovinos HF, Nayak TR, Theuer CP, et al. PET imaging of CD105/endoglin expression with a 61/64Cu-labeled Fab antibody fragment. Eur J Nucl Med Mol Imaging. 2013;40:759–67.
20. Rousseaux J, Rousseaux-Prevost R, Bazin H. Optimal conditions for the preparation of Fab and F(ab’)2 fragments from monoclonal IgG of different rat IgG subclasses. J Immunol Methods. 1983;64:141–6.
21. Chen F, Nayak TR, Goel S, Valdovinos HF, Hong H, Theuer CP, et al. In vivo tumor vasculature targeted PET/NIRF imaging with TRC105(Fab)-conjugated, dual-labeled mesoporous silica nanoparticles. Mol Pharm. 2014;11:4007–14.
22. Hewett PW, Murray C. Modulation of human endothelial cell procoagulant activity in tumour models in vitro. Int J Cancer. 1996;66:784–9.
23. Hjortoe GM, Petersen LC, Albrektsen T, Sorensen BB, Norby PL, Mandal SK, et al. Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood. 2004;103:3029–37.
24. Zhou J, Stenlinder M, Linder S. Tissue factor mRNA expression in breast carcinoma cells. Oncol Rep. 1996;3:443–5.
25. Zhou JN, Ljungdahl S, Shoshan MC, Swedenborg J, Linder S. Activation of tissue-factor gene expression in breast carcinoma cells by stimulation of the RAF-ERK signaling pathway. Mol Carcinog. 1998;21:234–43.
26. Orbay H, Zhang Y, Hong H, Hacker TA, Valdovinos HF, Zagzebski JA, et al. Positron emission tomography imaging of angiogenesis in a murine hindlimb ischemia model with 64Cu-labeled TRC105. Mol Pharm. 2013;10:2749–56.
27. Zhang Y, Hong H, Engle JW, Bean J, Yang Y, Leigh BR, et al. Positron emission tomography imaging of CD105 expression with a 64Cu-labeled monoclonal antibody: NOTA is superior to DOTA. PLoS One. 2011;6:e28005.
28. Ademuyiwa FO, Ellis MJ, Ma CX. Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancer. J Oncol. 2013;2013:219869.
29. Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist. 2011;16 Suppl 1:1–11.
30. Schmadeka R, Harmon BE, Singh M. Triple-negative breast carcinoma: current and emerging concepts. Am J Clin Pathol. 2014;141:462–77.
31. Tchou J, Sonnad SS, Bergey MR, Basu S, Tomaszewski J, Alavi A, et al. Degree of tumor FDG uptake correlates with proliferation index in triple negative breast cancer. Mol Imaging Biol. 2010;12:657–62.
32. Hama Y, Nakagawa K. Early distant relapse in early stage triple-negative breast cancer: usefulness of FDG-PET for diagnosis of distant metastases. Breast Cancer. 2013;20:191–3.
33. Dogan BE, Turnbull LW. Imaging of triple-negative breast cancer. Ann Oncol. 2012;23 Suppl 6:vi23–9.
34. Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/”triple-negative” breast cancer cell lines growing in vitro. Breast Cancer Res Treat. 2007;105:319–26.
35. Chakravarty R, Goel S, Valdovinos HF, Hernandez R, Hong H, Nickles RJ, et al. Matching the decay half-life with the biological half-life: ImmunoPET imaging with (44)Sc-labeled cetuximab Fab fragment. Bioconjug Chem. 2014;25:2197–204.
36. Shi S, Yang K, Hong H, Valdovinos HF, Nayak TR, Zhang Y, et al. Tumor vasculature targeting and imaging in living mice with reduced graphene oxide. Biomaterials. 2013;34:3002–9.